42 recruiting, 35 completed, 22 terminated, 21 active not recruiting. 98 Phase 1, 70 Phase 2, 4 Not applicable, 2 Phase 3, 1 Early Phase 1.
Follow Refractory Acute Myeloid Leukemia: new trials by email Literature Review of Refractory Acute Myeloid Leukemia trials Research Report on Refractory Acute Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | City of Hope Medical Center | 19 | 2026-12-14 | 2026-05-13 |
| Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-11-05 | 2026-10-08 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-10-01 | 2026-08-18 |
| A Study of CRD3874-SI in People With Leukemia CRD3874-SI - Acute Myeloid Leukemia, AML | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 24 | 2026-06-15 | 2026-09-22 |
| A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia | Phase 1 | Recruiting | National Cancer Institute (NCI) | 47 | 2026-06-09 | 2026-10-22 |
| Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Autologous Anti-CD83 CAR T-cells, Biospecimen Collection, Chest Radiography - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Recruiting | Roswell Park Cancer Institute | 26 | 2026-02-02 | 2026-09-24 |
| Clinical Study of LILRA6 CAR-T for the Treatment of R/R Acute Myeloid Leukemia Anti-LILRA6 CAR-T cells - Refractory Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 48 | 2025-12-01 | 2025-12-04 |
| MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Biospecimen Collection, Echocardiography Test, miR-126 Inhibitor miRisten - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 20 | 2025-10-24 | 2026-09-01 |
| Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Undifferentiated Leukemia | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 36 | 2025-09-23 | 2026-05-15 |
| Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes Biospecimen Collection, Bone Marrow Aspiration, Cirtuvivint - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Recruiting | National Cancer Institute (NCI) | 54 | 2025-08-15 | 2026-10-01 |
| A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 12 | 2025-07-30 | 2026-09-29 |
| Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome | Phase 1 | Withdrawn | City of Hope Medical Center | 2025-06-07 | 2025-05-25 | |
| Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 | Suspended | City of Hope Medical Center | 20 | 2025-04-25 | 2026-10-20 |
| CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF) CER-1236, Cyclophosphamide, Fludarabine - AML, Acute Myeloid Leukemia | Phase 1 | Recruiting | CERo Therapeutics Holdings, Inc. | 18 | 2025-04-07 | 2026-10-21 |
| TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Myeloid Leukemia | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 42 | 2025-03-12 | 2026-10-16 |
| Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML Tagraxofusp, Cladribine (CLAD), Cytarabine - Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | Stanford University | 20 | 2025-02-10 | 2026-04-14 |
| Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia WBC100 QD - AML (Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia | Phase 1 | Recruiting | Hangzhou Weben Pharma Co., Ltd | 36 | 2024-11-03 | 2026-10-16 |
| Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML Decitabine, Azacitidine, Mitoxantrone liposome, Cytarabine, G-CSF - AML, Relapsed Acute Myeloid Leukemia | Phase 2 | Recruiting | Beijing 302 Hospital | 20 | 2024-10-31 | 2024-12-27 |
| Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia Eltanexor, Venetoclax, Bone Marrow Aspiration and Biopsy - Relapsed Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome | Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 60 | 2024-08-14 | 2026-08-19 |
| VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS PD-1 inhibitor, Venetoclax, Decitabine, Azacytidine - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 2 | Recruiting | Beijing 302 Hospital | 67 | 2024-07-18 | 2024-08-05 |
Showing 20 of 143. Sign in to see all of them.
Leukemia, Myeloid, Acute (143) · Myelodysplastic Syndromes (46) · Leukemia, Biphenotypic, Acute (22) · Leukemia, Myelomonocytic, Chronic (21) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (15) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (9) · Blast Crisis (7) · Myeloproliferative Disorders (7) · Myelodysplastic-Myeloproliferative Diseases (6) · Hematologic Neoplasms (5) · Recurrence (5) · Anemia, Refractory, with Excess of Blasts (4) · Primary Myelofibrosis (4) · Blastic Plasmacytoid Dendritic Cell Neoplasm (3) · Hodgkin Disease (3)
Hematologic Diseases (143) · Hemic and Lymphatic Diseases (143) · Neoplasms by Histologic Type (143) · Neoplasms (142) · Leukemia (141) · Leukemia, Myeloid (141) · Bone Marrow Diseases (59) · Pathologic Processes (36) · Pathological Conditions, Signs and Symptoms (36) · Immune System Diseases (35) · Immunoproliferative Disorders (35) · Lymphatic Diseases (35) · Lymphoproliferative Disorders (35) · Disease Attributes (33) · Leukemia, Lymphoid (31)
Cytarabine (43) · venetoclax (39) · Injections (26) · Azacitidine (25) · Decitabine (23) · Specimen Handling (20) · Biopsy (16) · fludarabine (15) · fludarabine phosphate (15) · Cyclophosphamide (14) · Granulocyte Colony-Stimulating Factor (13) · Filgrastim (12) · CPX-351 (9) · decitabine and cedazuridine drug combination (9) · Cladribine (8)
M.D. Anderson Cancer Center (41) · National Cancer Institute (NCI) (16) · City of Hope Medical Center (14) · Fred Hutchinson Cancer Center (7) · OHSU Knight Cancer Institute (4) · University of Washington (4) · Beijing 302 Hospital (3) · Children's Oncology Group (3) · Roswell Park Cancer Institute (3) · Case Comprehensive Cancer Center (2) · Memorial Sloan Kettering Cancer Center (2) · Nanfang Hospital, Southern Medical University (2) · Northwestern University (2) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (2) · St. Jude Children's Research Hospital (2)
United States (120) · China (8) · Canada (2) · Russia (2) · Australia (1) · Austria (1) · France (1) · Spain (1)
Courtney DiNardo, MD (5) · Tapan M Kadia (4) · Gautam Borthakur (3) · Musa Yilmaz (3) · Naval Daver (3) · Nicholas Short (3) · Amanda Blackmon (2) · Brian A Jonas (2) · Courtney DiNardo (2) · Farhad Ravandi-Kashani (2) · Maria Luisa Sulis (2) · Mary-Elizabeth Percival (2) · Naval G Daver (2) · Vinod Pullarkat (2) · Abhishek Maiti (1)
PMID 40513054, PMID 42013378, PMID 29567781, PMID 29702001, PMID 30335787, PMID 32077361, PMID 32896301, PMID 33027528, PMID 33208914, PMID 33580980, PMID 33609248, PMID 33792630, PMID 34255353, PMID 34329576, PMID 34474640, PMID 34889407, PMID 34980577, PMID 35007144, PMID 35078972, PMID 35175355, PMID 35442137, PMID 36658425, PMID 36706355, PMID 36841758, PMID 36898933, PMID 37120593, PMID 37386016, PMID 37899297, PMID 38277619, PMID 38391202, PMID 38452788, PMID 39303729, PMID 39821392, PMID 39863139, PMID 40000842, PMID 40073835, PMID 40193193, PMID 40238563, PMID 40401707, PMID 40500616, PMID 40535475, PMID 40864984, PMID 40979071, PMID 41796974, PMID 42007254, PMID 42200455, PMID 42681647, PMID 42835577
P30CA033572 (12), P30CA015704 (5), P30CA016672 (4), UM1CA186644 (3), UM1CA186717 (3), UM1CA228823 (3), P01CA078902 (2), P30CA016058 (2), P30CA060553 (2), U01CA076576 (2), U10CA180886 (2), UM1CA186691 (2), UM1CA186709 (2), N01CM00100 (1), P01CA018029 (1)